PDCD1 and cancer: In particular, new ITs primarily aim to inhibit cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1) to enable T lymphocytes to attack cancer cells [5,6,7].